Ardent Health Investors Urged to Seek Lead Role Before March 9 in Securities Class Action

Overview

• Plaintiff firms including Pomerantz, Schall, Faruqi & Faruqi, Hagens Berman, Rosen Law, and ClaimsFiler are actively recruiting investors to pursue the lead‑plaintiff role.
• The lawsuit, Postiwala v. Ardent Health, Inc., No. 26‑cv‑00022, is filed in the U.S. District Court for the Middle District of Tennessee and covers investors who bought shares between July 18, 2024 and November 12, 2025.
• Filings allege Ardent used a rigid 180‑day reserve 'cliff' for uncollectible accounts despite touting detailed historical collection reviews, and that its malpractice coverage and reserves were inadequate.
• On November 12, 2025, Ardent reported a roughly $43 million Q3 revenue decrease after adopting the Kodiak RCA platform and using hindsight evaluations, and it lowered 2025 EBITDA guidance to $530 million–$555 million from $575 million–$625 million.
• Ardent also recorded a $54 million increase in professional liability reserves tied to New Mexico litigation and broader social inflation pressures, and the stock fell about 34% to $9.30 on November 13, 2025.